Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 16

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 16
---
.82 
  
    $2.16  
     56,250  
     6.21  
     56,250  
     6.21 

     10,633,988  
     6.00  
     10,335,848  
     5.93 

During the three months ended March 31, 2025 and 2024, the Company recognized stock-based compensation expense of $421,454 and $355,317,
respectively, related to the vesting of stock options. There was $306,427 unrecognized stock-based compensation expense as of March 31,
2025.

Warrants

The following is a summary of the Company’s
warrant activity for the three months ended March 31, 2025:

Schedule of Warrant Activity

    Number of Shares  
    Weighted Average Exercise Price per Share  
    Weighted Average Remaining Life (Years) 
  
    Outstanding as of December 31, 2024  
     1,359,375  
    $0.80  
     0.93 
  
    Granted  
     -  
     -  
     - 
  
    Forfeited  
     -  
     -  
     - 
  
    Outstanding as of March 31, 2025  
     1,359,375  
    $0.80  
     0.68 

    19

JUPITER NEUROSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2025

Note 6 – Stockholders’ Equity,
continued

Restricted Stock Units

As of March 31, 2025 and December 31, 2024 the Company had an
aggregate of 1,626,037
restricted stock units outstanding with an aggregate fair value of $2,195,550.

Note 7 – Commitments and Contingencies

Legal Matters

From time to time, claims are made against the
Company in the ordinary course of business, which could result in legal proceedings. Claims and associated litigation are subject to inherent
uncertainties and unfavorable outcomes could occur, which could have a material adverse effect on the Company’s results of operations
for that period or future periods. As of March 31, 2025, there were no pending or outstanding legal